Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
The study duration per participant will be up to 116 weeks.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant must be 18 (or country's age of majority if \>18) years to 70 years of age inclusive, at the time of signing the informed consent.
Participants with a history of signs and symptoms consistent with HS for at least 1 year prior to baseline.
Participants must have HS lesions present in at least 2 distinct anatomic areas (eg, left, and right axilla; or left axilla and left inguino-crural fold), 1 of which must be Hurley Stage II or Hurley Stage III.
Participant must have had an inadequate response to at least a 12-week trial of an oral antibiotic for treatment of HS
You may not be if
Participants with a diagnosis of inflammatory conditions other than HS (including but not limited to systemic lupus erythematosus, systemic sclerosis, myositis, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, multiple sclerosis, Behcet's disease, sarcoidosis, etc)
Any other active skin disease or condition (eg, bacterial, fungal, or viral infection) that may interfere with assessment of HS
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial
Clareo Health | Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
